The approval is an FDA approval for use in the united states which benefits Pfizer. Isreal, has not yet approved but is expected to shortly (where Protalix has exclusivity). The majority of candidates to use the drug are in Isreal. Pfizer has the rights to the US and not Israel. So when approved in Israel the PPS should go up quite a bit???
wrong. to date, about 6000 patients are treated globally which gives a market between 1 to 1.3 billion. the projected potential market is about 12000 so only half of the market is currently be treated. And those patients are not all in Isreal, to date, only 300 patients are treated in there. The US has about 2000 patients treated today.